Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know.
Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...
Achondroplasia, which affects around one in 20,000 babies, has just one approved treatment: BioMarin’s Voxzogo. However, new investigational treatments are vying to compete in the area. Achondroplasia ...
SAN FRANCISCO — Not many biotechs survive beyond 25 years, let alone get multiple drugs approved and turn a profit.
It seems Sony is rolling out a new sale for PS Plus Premium and Extra memberships. Details have surfaced ahead of the discounts, which will allow those looking to subscribe to save a good chunk on ...
BioMarin Pharmaceutical (BMRN) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. Studies have ...
BioMarin Pharmaceutical (BMRN ... A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback